Evaluation of the Effectiveness and Safety of Vibro-acoustic Pulmonary Therapy (VAPT) in Complex Therapy for Acute Respiratory Failure of Mixed Type I-II Stages in Comparison With Percussion Massage in Cardiac Surgical Patients in the Early Postoperative Period

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

310 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-20

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to evaluate the effectiveness and safety of vibro-acoustic pulmonary therapy (VAPT) in complex therapy for the acute respiratory failure of mixed type I-II stages in comparison with percussion massage in cardiac surgical patients in the early postoperative period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of the Force Frequency Relationship of the Myocardium After On-pump CABG Surgery

NCT02407574

Adult Cardiac Surgery

UNKNOWN NA

Pulse Wave Parameters in the Assessment of Systolic Function of the Left Ventricle.

NCT04788342

Hypertension Heart Failure

COMPLETED

Measurement of Pulmonary Transit Time by Echocardiography: Comparison With Cardiac MRI

NCT02088320

Patients Undergoing Cardiac Surgery

COMPLETED

Comparison of Cardiac Index and Stroke-volume-index Measured by Pulmonary Artery Catheter, FloTrac® and Argos® in Cardiac Surgery Patients.

NCT06918301

Cardiac Failure Acute Hemodynamic Monitoring

RECRUITING

A Study to Evaluate a Computerized Stethoscope Called ©Voqx to Diagnose Heart Disease

NCT04960280

Isolated Aortic Stenosis Mitral Regurgitation

ENROLLING_BY_INVITATION NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Surgical Patients (CABG,Mammary Coronary Bypass Surgery,Plastic and Replacement of Valves, Atrial Septal Defect,Ventricular Septal Defect)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group with percussion massage

No interventions assigned to this group

Group with vibroacoustic massage

Vibroacoustic device BARK VibroLUNG

Intervention Type DEVICE

The BARK VibroLUNG vibroacoustic device is intended for the treatment and prevention of respiratory pathologies.

The BARK VibroLUNG vibroacoustic device with accessories is a medical device and is intended for the treatment of pathological conditions associated with obstructive and restrictive lung diseases in patients in medical institutions.

Field of application: physiotherapy of the chest organs, treatment and prevention of respiratory failure.

The therapeutic mechanism of action is due to three main effects: improved bronchial drainage, improved ventilation-perfusion ratios, and the "lung opening" maneuver.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vibroacoustic device BARK VibroLUNG

The BARK VibroLUNG vibroacoustic device is intended for the treatment and prevention of respiratory pathologies.

The BARK VibroLUNG vibroacoustic device with accessories is a medical device and is intended for the treatment of pathological conditions associated with obstructive and restrictive lung diseases in patients in medical institutions.

Field of application: physiotherapy of the chest organs, treatment and prevention of respiratory failure.

The therapeutic mechanism of action is due to three main effects: improved bronchial drainage, improved ventilation-perfusion ratios, and the "lung opening" maneuver.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 18 years to 80 years inclusive
* Body mass index from 18.5 to 35
* Physical status according to ASA II to ASA III (inclusive)
* Performed planned cardiac surgery (CS) under general anaesthesia with tracheal intubation and mechanical ventilation lasting more than 3 hours using a heart-lung machine (no more than 120 minutes)
* Left ventricular injection fraction before surgical treatment is above 40%
* Development of postoperative mixed ARF grade 1-2 (clinical criteria). SpO2 less than 95% with FiO2 21%.
* Stable-severe condition of the patient according to vital signs:

1. stable hemodynamics (norepinephrine and/or adrenaline less than 0.15 mcg/kg/min, and/or dobutamine less than 10 mcg/kg/min, and/or no need for vasopressin (ADH) for 6 hours or more)
2. absence of acute kidney injury (urine output more than 500 ml/day)
3. stable respiratory dynamics.P/F more than 150 units, SpO2 more than 70% with FiO2 21%.Tracheal extubation within 8 hours of completion of surgery
4. absence of critical coagulopathy (platelets more than 50 units/l)
5. absence of acute cerebral insufficiency (GCS more than 12 points)
6. absence of acute liver failure (bilirubin less than 30 units/l)
* Relieved postoperative pain syndrome and delirium (NRS less than 5 points, BPS less than 6 points, CAM-ICU (-), RASS -3-0 points).

Exclusion Criteria

* The presence of implanted or external medical electronic-mechanical devices in the impact projection (pacemaker, circulatory support devices, etc.);
* Severe hypocoagulation, risk of hematoma formation or bleeding in the projection of exposure;
* Severe hypercoagulation, risk of formation and/or migration of blood clots or emboli along the great vessels in the projection of exposure;
* Acute cerebrovascular accident (ACB), first 1-3 days;
* Cerebral Edema;
* High intracranial pressure;
* The presence of many purulent or burn wound surfaces in the projection of exposure;
* Presence of an unstable rib fracture;
* Pneumohemomediastinum and/or subcutaneous emphysema of the chest;
* Risk of development of hemo-pneumothorax;
* Osteomyelitis of the ribs and/or thoracic spine;
* Spinal fracture without orthopedic fixation;
* Trauma to the chest or abdomen with bleeding;
* High risk of seizures (CNS pathologies);
* The presence of an oncological process in the projection of exposure with destruction of tumor tissue and the risk of bleeding and/or metastasis;
* The presence of endothoracic and/or large endovascular implants (aortic stents, intra-aortic balloon pumps, endocardial catheters, mechanical heart valves, vena cava filters, subcutaneous venous ports, permanent hemodialysis devices);
* Heart rhythm disturbances (ventricular fibrillation, ventricular tachycardia);
* Hypovolemia;
* Disturbances of water-electrolyte balance and acid-base balance;
* Meningoencephalitis;
* Destructive purulent pneumonia;
* High risk of pulmonary hemorrhage;
* Hiatal hernia;
* Risk of dislocation of implanted drainage tubes and catheters;
* The presence of multiple wound surfaces in the projection of exposure;
* Severe bullous deformation of the lungs;
* Severe kyphoscoliosis;
* Spontaneous pneumothorax within the last year;
* Estimated systolic pressure over the pulmonary artery more than 50 mm Hg. Art.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No